Tidal Investments LLC Buys New Shares in Personalis, Inc. $PSNL

Key Points

• Tidal Investments acquired 85,504 Personalis shares worth approximately $1.15 million, while institutional investors collectively own 61.91% of the company.
• Personalis shares opened at $16.40, near their 52-week high of $18.89. The company beat revenue expectations but missed quarterly EPS estimates, reporting a loss of $0.30 per share.
• Analyst sentiment is mixed, with four Buy, five Hold, and one Sell rating; the average price target is $14.54. Meanwhile, company insiders sold 256,233 shares worth about $3.57 million over the past 90 days.

Tidal Investments LLC bought a new position in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 85,504 shares of the company's stock, valued at approximately $1,146,000. Tidal Investments LLC owned approximately 0.08% of Personalis as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Merck & Co. Inc. acquired a new stake in shares of Personalis during the 2nd quarter valued at $188,202,236. BlackRock Inc. acquired a new position in shares of Personalis in the 2nd quarter worth $94,905,000. Bank of America Corp DE acquired a new stake in shares of Personalis during the second quarter worth $24,395,000. AIGH Capital Management LLC acquired a new stake in shares of Personalis during the second quarter worth $22,981,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Personalis by 8.4% during the first quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company's stock valued at $6,791,000 after purchasing an additional 83,074 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company's stock.

Personalis Trading Up 1.0%

Shares of NASDAQ PSNL opened at $16.40 on Friday. Personalis, Inc. has a one year low of $4.95 and a one year high of $18.89. The business has a 50-day moving average price of $15.04 and a two-hundred day moving average price of $10.83. The firm has a market capitalization of $1.72 billion, a PE ratio of -15.05 and a beta of 2.31.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.04). The business had revenue of $22.36 million during the quarter, compared to analyst estimates of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. Research analysts anticipate that Personalis, Inc. will post -1.07 EPS for the current year.

Insider Buying and Selling

In other Personalis news, CFO Aaron Tachibana sold 51,251 shares of Personalis stock in a transaction on Friday, June 26th. The shares were sold at an average price of $13.18, for a total transaction of $675,488.18. Following the completion of the sale, the chief financial officer owned 198,833 shares of the company's stock, valued at $2,620,618.94. This trade represents a 20.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the business's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the transaction, the chief executive officer owned 235,986 shares in the company, valued at approximately $3,558,668.88. This represents a 29.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 256,233 shares of company stock worth $3,568,236 over the last ninety days. 4.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PSNL. TD Cowen reissued a "buy" rating on shares of Personalis in a research note on Wednesday, July 15th. Craig Hallum lowered shares of Personalis from a "buy" rating to a "hold" rating and set a $16.25 price objective for the company. in a research note on Monday, August 24th. BTIG Research raised their target price on shares of Personalis from $11.00 to $16.25 and gave the stock a "buy" rating in a report on Monday, July 20th. Weiss Ratings reissued a "sell (d-)" rating on shares of Personalis in a research report on Friday, July 17th. Finally, Lake Street Capital lowered shares of Personalis from a "buy" rating to a "hold" rating and set a $16.25 price target on the stock. in a report on Monday, July 20th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $14.54.

Personalis Profile

Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis' technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.